To evaluate the safety and tolerability of treatment with an investigational drug versus a placebo in volunteers with a diagnosis of IPF. Secondary objectives will evaluate the effect of treatment with BMS-986020 on disease markers and lung function.
Participation will last for approximately 8 months and involve 14 outpatient visits. People enrolled in the study will take the study drug/placebo in pill form on a daily basis for 26 weeks. Study volunteers will be compensated up to $1250 for participation.
For more information, please contact the recruitment team at the Duke Clinical Research Unit at 919-613-6246 or email@example.com.
For more information,
contact Duke Clinical Research Unit at